US 12,458,691 B2
HIV-1 ENV fusion peptide immunogens and their use
Peter Kwong, Washington, DC (US); Rui Kong, Bethesda, MD (US); Tongqing Zhou, Boyds, MD (US); John Mascola, Rockville, MD (US); Kai Xu, Bethesda, MD (US); Cheng Cheng, Bethesda, MD (US); Gwo-Yu Chuang, Rockville, MD (US); Kevin Liu, Bethesda, MD (US); Baoshan Zhang, Bethesda, MD (US); Li Ou, Potomac, MD (US); and Wing-Pui Kong, Germantown, MD (US)
Assigned to The United States of America, as represented by the Secretary Department of Health and Human Services, Bethesda, MD (US)
Filed by The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Filed on Feb. 6, 2023, as Appl. No. 18/164,988.
Application 18/164,988 is a continuation of application No. 16/338,964, granted, now 11,602,559, previously published as PCT/US2017/054959, filed on Oct. 3, 2017.
Claims priority of provisional application 62/403,266, filed on Oct. 3, 2016.
Prior Publication US 2023/0338507 A1, Oct. 26, 2023
Int. Cl. C12N 7/00 (2006.01); A61K 39/21 (2006.01); A61K 47/64 (2017.01); A61P 31/18 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/21 (2013.01) [A61K 47/6415 (2017.08); A61K 47/643 (2017.08); A61K 47/646 (2017.08); A61P 31/18 (2018.01); C07K 14/005 (2013.01); C12N 7/00 (2013.01); A61K 2039/545 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6081 (2013.01); C07K 2319/40 (2013.01); C07K 2319/55 (2013.01); C12N 2740/16023 (2013.01); C12N 2740/16134 (2013.01); C12N 2740/16171 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An immunogen, comprising a human immunodeficiency virus type 1 (HIV-1) Env fusion peptide conjugated to a carrier protein by a heterologous linker, wherein:
the HIV-1 Env fusion peptide consists of the amino acid sequence of AVGIGAV (residues 1-7 of SEQ ID NO: 1) or AVGIGAL (residues 1-7 of SEQ ID NO: 6); and
the immunogen elicits a neutralizing immune response to HIV-1 in a subject.